Wearable Devices Assist in the Detection, Screening, and Management of Major Diseases in Middle-aged and Elderly Populations

Launched by TONGJI HOSPITAL · May 16, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring how effective Huawei smartwatches can be in detecting and managing serious health conditions in middle-aged and elderly adults, particularly those between 40 and 69 years old who may have risk factors for heart and brain diseases. The main focus is on whether using data from these smartwatches, with the help of artificial intelligence, can improve the detection of coronary artery disease compared to regular check-ups by doctors. The study also aims to see if this smartwatch approach can help reduce heart-related problems within a year.

To participate in this trial, individuals need to be 40-69 years old and have at least one risk factor for cardiovascular issues, such as high blood pressure, diabetes, or a history of smoking. Participants will wear the smartwatch to collect health data for 24 hours, undergo some health assessments, and receive a preliminary diagnosis. After a year, they will be checked again to see how they are doing. It’s important to note that those with certain serious heart conditions or specific health issues may not be eligible to join. This trial is not yet recruiting participants, but it aims to provide valuable insights into how technology can assist in healthcare for older adults.

Gender

ALL

Eligibility criteria

• The inclusion criteria are as follows:
• • 1. Aged more than equal to 40 years, less than 69 years.
• 2. Having at least one of the following conditions (with one risk factor for cardiovascular and cerebrovascular diseases):
• • ① Male ≥ 55 years old, female ≥ 65 years old; ② Smokers or those who quit smoking within the past 3 months prior to the visit; ③ Diabetes (type 1 or 2); ④ Hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg) or currently taking antihypertensive medication; ⑤ Dyslipidemia: total cholesterol ≥ 5.18mmol/L, triglycerides ≥ 1.70mmol/L, high-density lipoprotein\<1.04mmol or low-density lipoprotein ≥ 3.37mmol/L; ⑥ hsCRP\>3.0 mg/L; ⑦ 10-year ASCVD risk of 20% or more (calculated according to the formula designed in the PREVENT study)
• • 3. Agree to receive coronary CTA if suspected to have coronary artery stenosis.
• • 4. Voluntarily joined and signed the informed consent.
• The exclusion criteria:
• • 1. Previously diagnosed with CAD or considered moderate to severe coronary stenosis (CAD-RADS grade 3 or above: stenosis degree of 50% or above) through coronary CTA or coronary angiography examination.
• • 2. Pregnant women or women planning to become pregnant within the next year.
• • 3. During the onset of the disease and needs in-hospital treatment.
• • 4. Tattoos or other substances that affect optical signals on the wrist.
• • 5. Severe arrhythmia patients, including third degree atrioventricular block, ventricular escape rhythm, severe sinus bradycardia, sick sinus syndrome, supraventricular tachycardia, ventricular tachycardia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter.
• • 6. Physical disability, blindness, and deafness.
• • 7. Allergic history of contrast agent containing iodine.